X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUN PHARMA AJANTA PHARMA/
SUN PHARMA
 
P/E (TTM) x 21.1 15.9 132.2% View Chart
P/BV x 9.1 3.7 243.2% View Chart
Dividend Yield % 0.7 0.2 322.1%  

Financials

 AJANTA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
SUN PHARMA
Mar-16
AJANTA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,201 143.2%   
Low Rs1,103706 156.1%   
Sales per share (Unadj.) Rs194.6117.5 165.7%  
Earnings per share (Unadj.) Rs45.219.6 230.8%  
Cash flow per share (Unadj.) Rs50.323.8 211.3%  
Dividends per share (Unadj.) Rs8.001.00 800.0%  
Dividend yield (eoy) %0.60.1 540.4%  
Book value per share (Unadj.) Rs132.0130.5 101.2%  
Shares outstanding (eoy) m88.772,406.60 3.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.38.1 89.4%   
Avg P/E ratio x31.248.7 64.1%  
P/CF ratio (eoy) x28.140.1 70.1%  
Price / Book Value ratio x10.77.3 146.3%  
Dividend payout %17.75.1 346.7%   
Avg Mkt Cap Rs m125,2992,294,813 5.5%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m2,57047,971 5.4%   
Avg. sales/employee Rs ThNM19,169.8-  
Avg. wages/employee Rs ThNM3,253.0-  
Avg. net profit/employee Rs ThNM3,197.9-  
INCOME DATA
Net Sales Rs m17,275282,697 6.1%  
Other income Rs m1666,170 2.7%   
Total revenues Rs m17,442288,867 6.0%   
Gross profit Rs m5,80783,239 7.0%  
Depreciation Rs m45110,135 4.4%   
Interest Rs m494,769 1.0%   
Profit before tax Rs m5,47474,505 7.3%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m1,4609,349 15.6%   
Profit after tax Rs m4,01447,159 8.5%  
Gross profit margin %33.629.4 114.2%  
Effective tax rate %26.712.5 212.5%   
Net profit margin %23.216.7 139.3%  
BALANCE SHEET DATA
Current assets Rs m7,639308,646 2.5%   
Current liabilities Rs m2,715132,477 2.0%   
Net working cap to sales %28.562.3 45.7%  
Current ratio x2.82.3 120.8%  
Inventory Days Days4383 52.1%  
Debtors Days Days7988 89.7%  
Net fixed assets Rs m6,914133,606 5.2%   
Share capital Rs m1772,407 7.4%   
"Free" reserves Rs m11,442266,909 4.3%   
Net worth Rs m11,721314,042 3.7%   
Long term debt Rs m14931,167 0.5%   
Total assets Rs m14,814542,196 2.7%  
Interest coverage x112.916.6 679.4%   
Debt to equity ratio x00.1 12.8%  
Sales to assets ratio x1.20.5 223.7%   
Return on assets %27.49.6 286.4%  
Return on equity %34.215.0 228.1%  
Return on capital %46.517.8 262.1%  
Exports to sales %55.114.0 394.0%   
Imports to sales %6.03.1 191.2%   
Exports (fob) Rs m9,52739,572 24.1%   
Imports (cif) Rs m1,0388,882 11.7%   
Fx inflow Rs m10,42242,171 24.7%   
Fx outflow Rs m1,67821,583 7.8%   
Net fx Rs m8,74420,588 42.5%   
CASH FLOW
From Operations Rs m3,26467,694 4.8%  
From Investments Rs m-2,093-44,549 4.7%  
From Financial Activity Rs m-1,186-19,243 6.2%  
Net Cashflow Rs m-153,902 -0.4%  

Share Holding

Indian Promoters % 73.8 63.7 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.1 30.2%  
FIIs % 7.6 23.0 33.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.3 204.8%  
Shareholders   20,968 133,026 15.8%  
Pledged promoter(s) holding % 4.4 0.5 828.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS